-Bayer's Riociguat Meets Primary Endpoint in Pivotal Phase III Study in Patients with Pulmonary Arterial Hypertension.
ENP Newswire - 22 October 2012
Release date- 22102012 - Berlin, - Bayer HealthCare today announced positive data for riociguat from the pivotal Phase III study PATENT-1.
The study met its primary endpoint by demonstrating a statistically significant improvement in the six-minute walk test (6MWT), a predictor of improved outcome in patients suffering from pulmonary arterial hypertension (PAH).(1,2) Patients treated with riociguat showed an improvement of 36 meters (95%-CI [20-52 meters] p
((Distributed via M2 Communications - http://www.m2.com)).END.PUB430>PDOctober 22, 2012>JNTRAVEL BUSINESS REVIEW.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||Travel Business Review (TBR)|
|Date:||Oct 22, 2012|
|Previous Article:||-BIOTA -Merger update, determination of VWAP & share ratios.|
|Next Article:||-Bayer's Xarelto (Rivaroxaban) Recommended for EU Approval for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein...|